Drug-Induced Anaphylaxis in Children

Bianchi, Annamaria; Valluzzi, Rocco; Crisafulli, Giuseppe; Bottau, Paolo; Caimmi, Silvia; Franceschini, Fabrizio; Liotti, Lucia; Mori, Francesca; Riscassi, Sara; Saretta, Francesca; Scavone, Sara; Caffarelli, Carlo

doi:10.3390/biomedicines12030527

Cited by 2 publications

(2 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anaphylactic shock is a fatal allergic reaction ( Li et al, 2022 ). Compared to adult data, reports of drug-induced anaphylactic reactions (DIA) in children are rare ( Bianchi et al, 2024 ). DIA is primarily an IgE-mediated tachyphylactic reaction leading to the degranulation of mast cells and basophils and the release of pro-inflammatory mediators ( Pichler, 2003 ).…”

Section: Discussionmentioning

confidence: 99%

The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system

Wei,

Huang,

Bai

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

BackgroundOseltamivir and baloxavir marboxil are the two primary oral drugs approved by the Food and Drug Administration (FDA) for treating influenza. Limited real-world evidence exists on their adverse events in children. The purpose of this study was to explore the adverse event (AE) profiles of oseltamivir and baloxavir marboxil in children based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database.MethodsFAERS reports were collected and analyzed from the first quarter of 2019 to the third quarter of 2023. Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms, were employed in data mining to quantify the signals of oseltamivir and baloxavir marboxil-related AEs.ResultsA total of 464 reports of AEs to oseltamivir as the “primary suspect (PS)” and 429 reports of AEs to baloxavir marboxil as the “PS” were retrieved in pediatric patients. A total of 100 oseltamivir-induced AE signals were detected in 17 system organ classes (SOCs), and 11 baloxavir marboxil-induced AE signals were detected in 6 SOCs after complying with the four algorithms simultaneously. Categorized and summarized by the number of reports of involvement in each SOC, the top 3 for oseltamivir were psychiatric disorders, gastrointestinal disorders, general disorders and site-of-administration conditions, respectively. The top 3 for baloxavir marboxil were injury, poisoning and surgical complications, general disorders and site of administration conditions, and psychiatric disorders, respectively.ConclusionOur study identifies potential new AE signals for oseltamivir and provides a broader understanding of the safety of oseltamivir and baloxavir marboxil in children.

show abstract

Section: Discussionmentioning

confidence: 99%

The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system

Wei,

Huang,

Bai

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Topical, intramuscular, and intravenous routes of administration are more likely to cause allergic drug reactions than oral administration. Moreover, parental administration is associated with more severe reactions because of a more rapid absorption and presentation to immune system [ 80 , 129 , 131 ].…”

Section: Risk Factors Related To the Drugmentioning

confidence: 99%

Risk factors for drug hypersensitivity reactions in children

Mori,

Saretta,

Riscassi

et al. 2024

Ital J Pediatr

View full text Add to dashboard Cite

Drug hypersensitivity reactions are common in children. Risk factors predisposing to IgE-mediated drug allergies and delayed drug reactions are a matter of debate. Gender, age, previous reactions to the same drug or to another drug, reduced drug metabolism, chronic diseases, polypharmacy, drug doses are linked with the onset of hypersensitivity reactions in some children. Novel advances in genetic polymorphisms can rapidly change the approach to the prevention of reactions since gene testing can be a useful screening test for severe cutaneous adverse reactions. Viral infections may act as cofactors in susceptible individuals. Polypharmacy, high doses, repeated doses and parental route of administration are also risk factors. Clinicians should take into account risk factors to allow the risk–benefit balance to be maintained.

show abstract

Drug-Induced Anaphylaxis in Children

Cited by 2 publications

References 93 publications

The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system

The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system

Risk factors for drug hypersensitivity reactions in children

Contact Info

Product

Resources

About